Macrolide Antibiotics Market Size, Share, Growth Analysis, By Drug Type(Azithromycin, Erythromycin, and Others), By Route of Administration(Oral, Parenteral and Others), By Distribution Channel(Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers), By Region - Industry Forecast 2025-2032

Macrolide Antibiotics Market size was valued at USD 5.73 Billion in 2023 and is poised to grow from USD 5.86 Billion in 2024 to USD 6.87 Billion by 2032, growing at a CAGR of 2.3% during the forecast period (2025-2032).

Antibiotics belonging to the macrolide class have a macrocyclic lactone structure with one or more deoxy sugars attached. The macrolides bind irreversibly to a region on the 50S subunit of the bacterial ribosome to impede the translocation phases of protein synthesis. Even though they are usually thought of as bacteriostatic medications, larger dosages may have bactericidal effects. These macrolide antibiotics are used to treat sexually transmitted infections including gonorrhea and chlamydia and respiratory tract infections like pneumonia, bronchitis, sinusitis, and pharyngitis.

Globally rising infectious illness rates are the main factor fueling the market's expansion. The National Centre for Biotechnology Information (NCBI) estimates that between 1.5 and 14 instances of community-acquired pneumonia per 1000 people occur worldwide each year. Furthermore, there are 24.8 cases per 10,000 people in the United States each year, and the prevalence rises with age. The need for macrolide antibiotics as a treatment for community-acquired pneumonia is rising in the United States and other nations. This increases the market share of macrolide antibiotics. The market is growing as generic antibiotics are now more widely available. The goal of many market participants is to create generic equivalents of name-brand macrolide antibiotics.